ImaBiotech Supports the Institut Pasteur de Lille and Apteeus for the Development of Covid-19 Therapy
The high molecular specificity of Mass Spectrometry Imaging, combined with rapid method development highlighted the added value of this technique over other technologies.
- The high molecular specificity of Mass Spectrometry Imaging, combined with rapid method development highlighted the added value of this technique over other technologies.
- The next step is to demonstrate the medical value through a clinical trial, sponsored by the Institut Pasteur de Lille and led by Professor Benoit Deprez.
- Institut Pasteur de Lille is a private, non-profit foundation with recognized public utility status since 1898.
- As an international center for biomedical research, Institut Pasteur de Lille focuses on Longevity fundamental research, education and public health to ensure we live better for longer.